Colonized, Not Infected: Group B Strep in Pregnancy and the Protocol Built Around It

Key Takeaways:

• A meta-analysis pooling 390 studies across 85 countries and 299,924 pregnant women put maternal rectovaginal Group B strep colonization at 18 percent worldwide, with regional estimates ranging from 11 to 35 percent.
• About half of colonized women pass the organism to the newborn during birth, and in the absence of intrapartum antibiotics roughly 1 to 2 percent of those newborns develop early-onset disease — which is why the intervention targets the moment of passage rather than the colonization itself.
• Universal screening moved in 2020 from 35 to 37 weeks to a 36 0/7 to 37 6/7 week vaginal-rectal culture, and early-onset disease in the United States fell from 0.37 to 0.23 cases per 1,000 live births between 2006 and 2015 while late-onset disease held steady at about 0.31.

The single most useful sentence about Group B strep in pregnancy is that it describes a colonization state, not an infection. Streptococcus agalactiae lives in the gastrointestinal tract and moves back and forth to the genitourinary tract, and in most women who carry it there are no symptoms, no inflammation, no tissue invasion, and nothing to treat. The numbers are reassuringly ordinary: a systematic review pooling 390 studies from 85 countries and nearly 300,000 pregnant women estimated worldwide maternal colonization at 18 percent, with regional figures spread between 11 and 35 percent, which is where the familiar clinical shorthand of one in four to one in five comes from. Follow the chain forward and it stays modest. About half of colonized women transmit the organism to the newborn during labor or after membranes rupture, and without intrapartum antibiotics roughly 1 to 2 percent of those exposed newborns go on to develop early-onset disease. That is a small number built out of a common condition, and it explains the entire design of the protocol: the target is not the mother’s flora, which is normal, but the inoculum present in the birth canal during the hours the infant passes through it.

That distinction is why screening sits where it does in the calendar. Carriage is intermittent — a woman culture-positive at 30 weeks may be negative at term and the reverse is equally true — so a culture is only a reliable proxy for labor-time status within a limited window ahead of delivery. Testing too early produces results that have expired by the time they are needed. Current guidance therefore places the universal vaginal-rectal culture at 36 0/7 to 37 6/7 weeks of gestation, a deliberate shift made in 2020 from the older 35-to-37-week window, so that the result still holds for pregnancies that continue past the due date. The specimen matters as much as the timing: a swab of the lower vagina followed by the rectum, through the anal sphincter, because a vaginal-only swab misses a meaningful share of carriers whose primary reservoir is intestinal. A positive result changes exactly one thing — it schedules intravenous penicillin during labor, ideally begun at least four hours before delivery, with prophylaxis omitted when a prelabor cesarean is performed with membranes intact.

What does intrapartum penicillin actually change about Group B strep in pregnancy?

Not the colonization. Penicillin given in labor does not eradicate carriage, and a woman treated in one pregnancy may screen positive in the next. What it does is drive the bacterial density in the birth canal down and put drug into the amniotic fluid and fetal circulation before the infant makes the passage, which is why the four-hour threshold keeps appearing in the guidance — shorter exposures are measurably less protective than four or more hours of a beta-lactam. It is a narrow, mechanical intervention aimed at a narrow window, and its results have been correspondingly precise. Across a decade of United States population-based surveillance, invasive early-onset disease fell from 0.37 to 0.23 cases per 1,000 live births. The honest counterpart to that success is what the protocol cannot do. Over the same decade, late-onset disease — infection appearing from day seven through day 89 — held essentially flat at about 0.31 cases per 1,000 live births. That is not a failure of intrapartum prophylaxis; it is a boundary condition. Antibiotics given during labor act on a single exposure at a single moment, and late-onset disease arrives days to weeks later by routes that moment never touched. Knowing that boundary is what keeps expectations calibrated in both directions: a positive culture is not a diagnosis, does not mean anything is wrong with the pregnancy, and does not change the birth plan beyond an IV line and a clock; and a completed course of prophylaxis, while genuinely one of the most effective preventive maneuvers in obstetrics, is a reason for continued ordinary newborn attention rather than a certificate against everything that follows.

References:

1. Russell, N. J., Seale, A. C., O’Driscoll, M., O’Sullivan, C., Bianchi-Jassir, F., Gonzalez-Guarin, J., et al. (2017). Maternal colonization with group B Streptococcus and serotype distribution worldwide: Systematic review and meta-analyses. Clinical Infectious Diseases, 65(Suppl 2), S100-S111.
2. American College of Obstetricians and Gynecologists. (2020). Prevention of group B streptococcal early-onset disease in newborns: ACOG Committee Opinion, Number 797. Obstetrics & Gynecology, 135(2), e51-e72.
3. Nanduri, S. A., Petit, S., Smelser, C., Apostol, M., Alden, N. B., Harrison, L. H., et al. (2019). Epidemiology of invasive early-onset and late-onset group B streptococcal disease in the United States, 2006 to 2015: Multistate laboratory and population-based surveillance. JAMA Pediatrics, 173(3), 224-233.